69
Views
0
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Case-Finding and Treatment Effects in COPD: Secondary Analysis of an Interdisciplinary Intervention Trial

ORCID Icon, ORCID Icon &
Pages 451-458 | Received 14 Sep 2023, Accepted 26 Dec 2023, Published online: 14 Feb 2024

References

  • Mangione CM, Barry MJ, Nicholson WK.; US Preventive Services Task Force. Screening for chronic obstructive pulmonary disease: US preventive services task force reaffirmation recommendation statement. JAMA. 2022;327(18):1806–1811. doi:10.1001/jama.2022.5692
  • Guirguis-Blake JM, Senger CA, Webber EM, Mularski RA, Whitlock EP. Screening for chronic obstructive pulmonary disease. JAMA. 2016;315(13):1378. doi:10.1001/jama.2016.2654
  • Han MK, Agusti A, Celli BR, et al. From GOLD 0 to Pre-COPD. Am J Respir Crit Care Med. 2021;203(4):414–423. doi:10.1164/rccm.202008-3328PP
  • Yang I, George J, McDonald C, et al. The COPD-X plan: Australian and New Zealand Guidelines for the management of chronic obstructive pulmonary disease. TSANZ [Internet]; Version 2; 2022. Available from: https://copdx.org.au/. Accessed January 26, 2024.
  • Lung Foundation of Australia. COPD case finding position paper; 2019; Available from: https://lungfoundation.com.au/resources/copd-case-finding-position-paper/. Accessed January 26, 2024.
  • Bragadottir GH, Halldorsdottir BS, Ingadottir TS, Jonsdottir H. Patients and families realising their future with chronic obstructive pulmonary disease—A qualitative study. J Clin Nurs. 2018;27(1–2):57–64. doi:10.1111/jocn.13843
  • Ansari S, Hosseinzadeh H, Dennis S, Zwar N. Patients’ perspectives on the impact of a new COPD diagnosis in the face of multimorbidity: a qualitative study. NPJ Prim Care Respir Med. 2014;24(1):14036. doi:10.1038/npjpcrm.2014.36
  • Clair C, Mueller Y, Livingstone-Banks J, et al. Biomedical risk assessment as an aid for smoking cessation. Cochrane Database Syst Rev. 2019;3(3):CD004705. doi:10.1002/14651858.CD004705.pub5
  • Liang J, Abramson MJ, Zwar N, et al. Interdisciplinary model of care (RADICALS) for early detection and management of chronic obstructive pulmonary disease (COPD) in Australian primary care: study protocol for a cluster randomised controlled trial. BMJ Open. 2017;7(9):e016985. doi:10.1136/bmjopen-2017-016985
  • Liang J, Abramson MJ, Russell G, et al. Interdisciplinary COPD intervention in primary care: a cluster randomised controlled trial. Eur Respir J. 2019;53(4):1801530. doi:10.1183/13993003.01530-2018
  • Yang IA, Brown JL, George J, et al. COPD‐X Australian and New Zealand guidelines for the diagnosis and management of chronic obstructive pulmonary disease: 2017 update. Med J Aust. 2017;207(10):436–442. doi:10.5694/mja17.00686
  • Jessup RL. Interdisciplinary versus multidisciplinary care teams: do we understand the difference? Aust Heal Rev. 2007;31(3):330–331.
  • Schrijvers G. Disease management: a proposal for a new definition. Int J Integr Care. 2009;9(1). doi:10.5334/ijic.301
  • Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation: the St. George’s Respiratory Questionnaire. Am Rev Respir Dis. 1992;145(6):1321–1327. doi:10.1164/ajrccm/145.6.1321
  • Benowitz NL, Jacob P, Ahijevych K; SRNT Subcommittee on Biochemical Verification. Biochemical verification of tobacco use and cessation. Nicotine Tob Res. 2002;4(2):149–159. doi:10.1080/14622200210123581
  • Borland R, Yong -H-H, O’Connor RJ, Hyland A, Thompson ME. The reliability and predictive validity of the Heaviness of Smoking Index and its two components: findings from the International Tobacco Control Four Country study. Nicotine Tob Res. 2010;12(suppl_1):S45–S50. doi:10.1093/ntr/ntq038
  • Biener L, Abrams DB. The Contemplation Ladder: validation of a measure of readiness to consider smoking cessation. Heal Psychol. 1991;10(5):360. doi:10.1037/0278-6133.10.5.360
  • Niaura R, Shadel WG. Assessment to Inform Smoking Cessation Treatment. In: The Tobacco Dependence Treatment Handbook: A Guide to Best Practices. Guilford Press; 2003.
  • Velicer WF, Diclemente CC, Rossi JS, Prochaska JO. Relapse situations and self-efficacy: an integrative model. Addict Behav. 1990;15(3):271–283. doi:10.1016/0306-4603(90)90070-E
  • Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Leidy NK. Development and first validation of the COPD assessment test. Eur Respir J. 2009;34(3):648–654. doi:10.1183/09031936.00102509
  • Mahler DA, Wells CK. Evaluation of clinical methods for rating dyspnea. Chest. 1988;93(3):580–586. doi:10.1378/chest.93.3.580
  • Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004;350(10):1005–1012. doi:10.1056/NEJMoa021322
  • Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand. 1983;67(6):361–370. doi:10.1111/j.1600-0447.1983.tb09716.x
  • Jones PW, Tabberer M, Chen W-H. Creating scenarios of the impact of COPD and their relationship to COPD assessment test (CATTM) scores. BMC Pulm Med. 2011;11(1):42. doi:10.1186/1471-2466-11-42
  • Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease [Internet]; 2023. Available from: https://goldcopd.org/2023-gold-report-2/. Accessed January 26, 2024.
  • StataCorp. Stata Statistical Software: Release 16.1. College Station, TX: StataCorp LLC; 2019.
  • Kruis AL, Ställberg B, Jones RCM, et al. Primary care COPD patients compared with large pharmaceutically-sponsored COPD studies: an UNLOCK validation study. PLoS One. 2014;9(3):e90145. doi:10.1371/journal.pone.0090145